FCC Chairman Raises Competition Concerns Over Netflix–Warner Bros. Discovery Deal 
Airbus CEO Warns Staff to Prepare for Rising Geopolitical Risks Amid Trade Tensions 
SEC Drops Gemini Enforcement Case After Full Repayment to Earn Investors 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
Ericsson Plans SEK 25 Billion Shareholder Returns as Margins Improve Despite Flat Network Market 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
Tesla Plans FSD Subscription Price Hikes as Autonomous Capabilities Advance 
NTSB Opens Investigation Into Waymo Robotaxis After School Bus Safety Violations in Texas 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos 
Microsoft Restores Microsoft 365 Services After Widespread Outage 
Hermès Menswear Marks Historic Transition as Véronique Nichanian Bids Farewell in Paris 
Exxon Mobil’s XTO Energy Explores Sale of Eagle Ford Shale Assets in South Texas 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
CN Energy Group Inc. Stock Slides After Nasdaq Delisting Notice Over Bid Price Rule 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
PARSIPPANY, N.J., May 10, 2017 -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that members of its management team are scheduled to present at the Bank of America Merrill Lynch 2017 Healthcare Conference at 8:00 AM PT on Wednesday, May 17, 2017 in Las Vegas.
A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archived on the Pacira website for two weeks following the presentation date.
About Pacira
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension), indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia, was commercially launched in the United States in April 2012. EXPAREL and two other products have successfully utilized DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. Additional information about Pacira is available at www.pacira.com.
Company Contact: Pacira Pharmaceuticals, Inc. Susan Mesco (973) 451-4030 [email protected]
